Quotes 5-day view Delayed Nasdaq
Estimated financial data (e) (USD)
Net income 2021
Net Debt 2021
P/E ratio 2021
Net income 2022
Net Debt 2022
P/E ratio 2022
Capi. / Sales 2021
Capi. / Sales 2022
Nbr of Employees
Novan, Inc. is a late clinical-stage biotechnology company. The Company is focused on leveraging its nitric oxide (NO)-based technology platform, NITRICIL, to generate macromolecular new chemical entities (NCEs) to treat multiple indications in dermatology, menâ€™s and womenâ€™s health, infectious diseases, and various other medical conditions. The Company has clinical-stage dermatology drug candidates with...
All news about NOVAN, INC.
11/30 NOVAN, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial O..
11/12 Novan to Participate in the Virtual Investor Roundtable Event
11/10 NOVAN, INC. : Management's Discussion and Analysis of Financial Condition and Results
11/10 Novan Provides Corporate Update and Reports Third Quarter 2021 Financial Results - Form..
11/10 NOVAN, INC. : Results of Operations and Financial Condition (form 8-K)
11/10 Earnings Flash (NOVN) NOVAN Reports Q3 Revenue $737,000, vs. Street Est of $0.752M
11/10 NOVAN : Q3 Earnings Snapshot
11/10 Novan, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Septem..
11/09 Novan Says Preclinical Data Back Plan to Advance COVID-19 Drug Candidate
11/09 Novan Plans to Advance SB019 for Treatment of Covid-19
11/09 Novan Announces Favorable Preclinical Safety Data and Intent to Advance SB019 for Treat..
11/09 Novan, Inc. Announces Favorable Preclinical Safety Data and Intent to Advance SB019 for..
11/04 Novan Announces Fireside Chat Hosted by Jonathan Aschoff, Ph.D. of ROTH Capital Partner..
11/03 Novan to Report Third Quarter 2021 Financial Results on November 10, 2021
11/02 Novan Receives Conditional FDA Acceptance for Antiviral Gel Brand Name
News in other languages on NOVAN, INC.
Analyst Recommendations on NOVAN, INC.
Technical analysis trends NOVAN, INC.
Short Term Mid-Term Long Term Trends Bearish Bearish Bearish
Number of Analysts
Last Close Price
Average target price
Spread / Average Target